Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer

[...]the anti-TNBC effects of hsa-miR-105-5p downregulation in vitro and in vivo will be studied. [...]cell cycle analysis showed that G2/M phase arrest occurred in MDA-MB-231 and MDA-MB-468 cells transfected with hsa-miR-105-5p inhibitor [Supplementary Figure 2, http://links.lww.com/CM9/B553]. Furthermore, this research identified PLCL1 as a downstream gene for hsa-miR-105-5p since silencing of PLCL1 could partly restore the cell proliferation, migration, invasion, and lipid accumulation induced by the downregulation of hsa-miR-105-5p in MDA-MB-231 and MDA-MB-468 cells. [...]according to the previous bioinformatics analysis, the role of hsa-miR-105-5p in TNBC cells was further verified in the present study, and hsa-miR-105-5p acts as an oncogene to promote the proliferation, metastasis, and lipid accumulation of TNBC cells by targeting PLCL1/UCP1 axis, which provides a new